<DOC>
	<DOC>NCT00152022</DOC>
	<brief_summary>The purpose of this study is to assess the safety and effectiveness of SPD465 compared to placebo (a capsule with no medication in it) in the treatment of ADHD. The study will also look at how SPD465 affects the participants sleep and how they perceive their quality of life.</brief_summary>
	<brief_title>Efficacy and Safety of SPD465 in Adults With Moderately Symptomatic ADHD.</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Amphetamine</mesh_term>
	<mesh_term>Dextroamphetamine</mesh_term>
	<mesh_term>Adderall</mesh_term>
	<criteria>Primary diagnosis of ADHD Baseline ADHDRSIV score &gt;= 32 Nonpregnant females of childbearing potential must comply with contraceptive restrictions. Significantly underweight or morbidly obese Comorbid psychiatric diagnosis with significant symptoms such as Axis II disorders or severe Axis I disorders History of seizure, tic disorder, or a current diagnosis and/or family history of Tourette's Disorder Females who are pregnant or lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>